Sumant Ramachandra Buys 200,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Sumant Ramachandra purchased 200,000 shares of the firm’s stock in a transaction on Friday, March 21st. The stock was acquired at an average cost of $0.58 per share, with a total value of $116,000.00. Following the transaction, the director now directly owns 200,000 shares in the company, valued at $116,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Lyell Immunopharma Stock Performance

LYEL stock opened at $0.56 on Thursday. Lyell Immunopharma, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $3.15. The company’s 50 day moving average price is $0.61 and its 200 day moving average price is $0.87. The firm has a market capitalization of $164.68 million, a price-to-earnings ratio of -0.71 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The firm had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. Equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a report on Thursday, March 13th.

Institutional Trading of Lyell Immunopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Intech Investment Management LLC acquired a new position in shares of Lyell Immunopharma during the 3rd quarter worth about $52,000. Erste Asset Management GmbH purchased a new stake in Lyell Immunopharma during the third quarter worth approximately $82,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Lyell Immunopharma in the third quarter valued at approximately $52,000. Centiva Capital LP purchased a new position in Lyell Immunopharma in the third quarter valued at approximately $31,000. Finally, State Street Corp raised its holdings in Lyell Immunopharma by 1.9% during the third quarter. State Street Corp now owns 3,889,553 shares of the company’s stock worth $5,368,000 after purchasing an additional 71,233 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.